Friday, 16 Feb 2018

You are here

Laparoscopic Gastric Sleeve Compared to Bypass Bariatric Surgery

JAMA reports the results of a 5 year Finnish study comparing the results of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass and shows that gastric bypass yielded greater weight loss at 5 years, the difference was not statistically significant, in patients with morbid obesity. 

The Sleeve vs Bypass (SLEEVEPASS) study included 240 adults with morbid obesity received open-label randomized intervention iwth either sleeve gastrectomy or gastric bypass with a 5-year follow-up period. The primary end point was weight loss evaluated by percentage excess weight loss. The pPrespecified equivalence margins were −9% to +9% excess weight loss.

The patients had a mean baseline BMI of 45.9, and 42.1% had type 2 diabetes, 34.6% dyslipidemia, and 70.8% hypertension.  The results are shown in the table below:

 SleeveBypass
% Wt. Loss49%57%
DM remission37%45%
D/C Statins47%60%
D/C BP meds29%51%
Morbidity rate19%26%

 

 

 

 

 

 

 

 

While gastric bypass results were generally superior to gastric sleeve results, these were not significantly different. 

These results are similar to that seen in the STAMPEDE study showing similar (nonsignificant) but better results for bypass compared to gastric sleeve in the control of type II diabetes. (citation source: https://buff.ly/2rdYC3M

The five-year follow-up of this original study showed that:

  • 88% of gastric bypass and sleeve gastrectomy patients maintained healthy blood glucose levels without needinginsulin.
  • 29% of gastric bypass patients and 23% of sleeve gastrectomy patients achieved normal blood glucose levels
  • Weight loss was significantly greater with gastric bypass and sleeve gastrectomy compared than with medications 

The effects of both surgical procedures to normalize glucose levels did, however, diminish over time, and some late complications were noted with surgery.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Methotrexate May Help in Chronic Chikungunya Arthritis

Methotrexate may provide benefits in treatment of the chronic arthritis that can persist following acute chikungunya virus infection, but definitive evidence remains lacking, researchers reported.

15% of Users Exceed Recommended OTC NSAID Dosing

New data shows that nearly 15 percent of adult ibuprofen users exceed the maximum recommended dose of ibuprofen or other NSAIDs in a one-week period. 

An online study analyzed NSAID use with a 1-week diary study that included 1326 ibuprofen users. The vast majority (90%) of ibuprofen use was from over-the-counter use.

2018 Predictions for Rheumatology

MedPage Today Editors surveyed a few rheumatologists for their major news predictions in 2018. Read on for predictions regarding drug pricing, biosimilars, autoimmunity and checkpoint inhibitors, and thrombotic events and JAK inhibition.

PRECISION Subanalyses Question Aspirin Use

The PRECISION trial reported last year that celecoxib appears to be safer than the NSAIDs naproxen or ibuprofen in treating osteoarthritis (OA) and rheumatoid arthritis patients who are at increased cardiovascular risk. New data suggests that adding aspirin may nullify this advantage, according to a study presented at the annual American Heart Association meeting and reported by Medscape.

Physician Visit Times Vary Worldwide

A metanalysis published in BMJ Open shows that for half of the world’s population, primary care doctor visits last less than five minutes and that the range is from 48 seconds in Bangladesh to 22.5 minutes in Sweden (US PCP visit averages at 20 minutes).